MaaT Pharma Q1 2026 Update: Financials, Business Progress, and Strategic Outlook
Decision brief
Answer first · skim in under a minute
MaaT Pharma reported EUR 0.8 million in Q1 2026 revenues following its transition to selling MaaT013 (Xervyteg®) to Clinigen for European distribution. The company highlighted a 19% year-over-year increase in MaaT013 revenues on a like-for-like basis.
MaaT Pharma's Q1 2026 update centers on MaaT013 (Xervyteg): EUR 0.8 million in Early Access Program revenues, EUR 18.1 million cash at March 31, 2026, and a May 2026 CHMP negative trend opinion on the European marketing authorization application.
Contents10 sections
Key Takeaways
- Q1 2026 revenues were EUR 0.8 million after the Clinigen Early Access Program transition.
- Cash stood at EUR 18.1 million on March 31, 2026; EIB Tranche B of EUR 6 million was drawn in April 2026.
- Like-for-like MaaT013 Early Access demand rose 19% year over year, per the company release.
- CHMP issued a negative trend opinion on the MaaT013 marketing authorization application in May 2026.
What Did MaaT Pharma Report for Q1 2026?
In its May 26, 2026 business update, MaaT Pharma (Euronext: MAAT) reported EUR 0.8 million in first-quarter 2026 revenues from the Early Access Program for MaaT013. Reported EAP revenues were EUR 1.1 million in Q1 2025. The company said the accounting change after selling product to Clinigen from January 2026 explains much of the year-over-year decline. On a like-for-like basis, it said MaaT013 revenues rose 19%. The figures are in the Business Wire release.
How Does the Clinigen Transition Affect Revenue?
Since January 2026, MaaT Pharma sells MaaT013 to Clinigen, which supplies European hospitals under Early Access. Reported company income is therefore based on transfer price and royalties under the licensing terms. Management said Q1 2026 net income on that basis was EUR 0.8 million and would have been EUR 1.3 million pre-transition. Investors comparing 2025 and 2026 EAP lines should adjust for that structural change rather than treat the headline drop as a pure demand signal.
Cash Runway and EIB Financing
Cash and cash equivalents were EUR 18.1 million as of March 31, 2026, down from EUR 24.9 million at December 31, 2025. That quarter-end figure excludes the April 2026 drawdown of Tranche B of the European Investment Bank loan, totaling EUR 6 million. With that drawdown and operating discipline, the company said cash runway extends into November 2026—coverage intended to bridge the planned CHMP re-examination steps for MaaT013.
- Cash March 31, 2026: EUR 18.1 million
- Cash December 31, 2025: EUR 24.9 million
- EIB Tranche B (April 2026): EUR 6 million
- Stated runway: into November 2026
What Is the EMA Path for MaaT013?
In May 2026 the company said it was informed of a CHMP “negative trend” opinion on its Marketing Authorization Application for MaaT013 (Xervyteg), ahead of an expected formal CHMP vote. It plans to request re-examination after the formal opinion. EMA's public materials explain how marketing authorization and CHMP opinion procedures work for human medicines; see the EMA marketing authorisation overview. A negative trend is not the final formal opinion, but it is a clear regulatory setback for near-term EU approval timing.
Where Is MaaT013 in Clinical Development?
MaaT013 is a pooled allogeneic fecal microbiota product developed for steroid-refractory gastrointestinal acute graft-versus-host disease. The pivotal ARES salvage study is registered as NCT04769895 on ClinicalTrials.gov. Related Early Access and prior GI-aGVHD studies include NCT04768907 and NCT03359980. At EBMT 2026, the company said ARES data featured in a Presidential Session oral presentation, with additional posters from PHOEBUS, CHRONOS, and THRASSA programs—congress presentation claims that still require reading the primary abstracts for endpoint detail.
What Remains Unproven
The Q1 release confirms cash, EAP revenue accounting, and a CHMP negative trend signal. It does not prove that re-examination will reverse the opinion, nor does it publish full pivotal efficacy tables in the earnings note. Independent confirmation of the 19% like-for-like growth depends on company methodology disclosed in the release. Formal CHMP opinion timing and any post-authorization commitments remain open.
Related NovaPharma coverage
- MaaT Pharma regulatory update on MaaT013 (Xervyteg)
- MaaT Pharma Q1 2026 business update companion coverage
- EMA liver safety checks for Tavneos (avacopan)
Frequently Asked Questions
What were MaaT Pharma Q1 2026 revenues?
MaaT Pharma reported EUR 0.8 million in Q1 2026 revenues tied to the Early Access Program after the Clinigen transition, versus EUR 1.1 million reported EAP revenues in Q1 2025.
What is MaaT Pharma's cash position?
Cash and cash equivalents were EUR 18.1 million as of March 31, 2026, versus EUR 24.9 million at December 31, 2025, before counting the April 2026 EUR 6 million EIB Tranche B drawdown.
What is the EMA status of MaaT013?
In May 2026 MaaT Pharma reported a CHMP negative trend opinion on its MaaT013 (Xervyteg) marketing authorization application and said it plans to request re-examination after the formal opinion.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for MaaT013.
Unlock full calendar →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
